Compare BEAM & CENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEAM | CENX |
|---|---|---|
| Founded | 2017 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Aluminum |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | 2020 | 1996 |
| Metric | BEAM | CENX |
|---|---|---|
| Price | $26.68 | $32.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $48.09 | $33.00 |
| AVG Volume (30 Days) | ★ 2.0M | 1.9M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.83 |
| Revenue | $55,701,000.00 | ★ $2,525,100,000.00 |
| Revenue This Year | N/A | $16.07 |
| Revenue Next Year | $26.52 | N/A |
| P/E Ratio | ★ N/A | $37.84 |
| Revenue Growth | N/A | ★ 20.15 |
| 52 Week Low | $13.53 | $13.05 |
| 52 Week High | $35.25 | $34.52 |
| Indicator | BEAM | CENX |
|---|---|---|
| Relative Strength Index (RSI) | 55.81 | 60.12 |
| Support Level | $25.86 | $31.17 |
| Resistance Level | $28.10 | $33.06 |
| Average True Range (ATR) | 1.56 | 1.23 |
| MACD | 0.17 | 0.26 |
| Stochastic Oscillator | 57.39 | 81.14 |
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. Century purchases nearly all of its alumina from Glencore. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. Century also owns a carbon anode production facility in the Netherlands.